Clinical trials: Diastolic Heart Failure
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure, Diastolic
CCM in Heart Failure With Preserved Ejection Fraction
This pilot study will evaluate the efficacy and safety of CCM therapy in heart failure patients with baseline EF≥50% (HFpEF) who have New York Heart Association (NYHA) Class II or III symptoms despite appropriate medication.
- Trial name
- CCM-HFpEF (NCT03240237)
- Testing
- Optimizer SMART
- Where
- 17 sites in Australia, Czechia and 6 more
- Volunteers
- 47 people
- Sponsor
- Impulse Dynamics
Diastolic Heart Failure
Ranolazine in Diastolic Heart Failure
Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled.
- Trial name
- RALI-DHF (NCT01163734)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Heart Failure, Congestive, Dyspnea
The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic…
- Conditions
- Heart Failure, Congestive, Dyspnea, Pulmonary Edema
- Trial name
- NCT00043836
- Testing
- ALT-711
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Synvista Therapeutics, Inc
Diastolic Heart Failure
A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
The purpose of the study is to gather information regarding the safety and effectiveness of an investigational drug called Alagebrium when used treating Heart Failure in relation to exercise tolerance after 6 months in the trial.
- Trial name
- BREAK-DHF-1 (NCT01913301)
- Testing
- Alagebrium
- Volunteers
- 134 people
- Sponsor
- Cardiovascular Clinical Sciences Inc
Hypertension, Pulmonary, Ventricular Dysfunction, Left
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction
- Trial name
- DILATE (NCT01172756)
- Testing
- Riociguat (BAY63-2521)
- Where
- 7 sites in Austria, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Bayer
Heart Failure With Normal Ejection Fraction
ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study
This study is designed to evaluate the ImCardia safety and to demonstrate system functionality in patients undergoing AV replacement with respect to 36 months follow up.
- Trial name
- ImCardia (NCT01347125)
- Testing
- ImCardia Device
- Volunteers
- 19 people
- Sponsor
- CorAssist Cadiovascular Ltd.
Heart Failure
Rheos System for the Treatment of HFpEF Heart Failure
The purpose of this clinical investigation (NCT00957073) is to continue long-term follow-up of device arm subjects enrolled in the HOPE4HF Trial, utilizing the BAROSTIM NEO™ LEGACY device for Implantable Pulse Generator (IPG)…
- Trial name
- HOPE4HF (NCT00957073)
- Testing
- Rheos® system
- Where
- 22 sites in United States
- Volunteers
- 19 people
- Sponsor
- CVRx, Inc.
Diastolic Heart Failure, Diastolic Dysfunction
CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)
The study objective is to demonstrate safety and feasibility of the CORolla® TAA during 12 months of follow up, and to evaluate the performance of the therapy in relieving symptoms and restore diastolic function in patients with…
- Trial name
- NCT02499601
- Testing
- CORolla™ TAA device
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- CorAssist Cadiovascular Ltd.
Chronic Stable Heart Failure
Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus
This study will be conducted as a randomized, multi-centre, double-blind, parallel-group, placebo-controlled study in patients receiving SoC therapy.
- Trial name
- NCT04507347
- Testing
- TRC041266
- Sponsor
- Torrent Pharmaceuticals Limited
Heart Failure, Diastolic, Edema Brain
Feasibility Study of a New Peripheral Oedema Monitor for Heart Failure
The study aims at assessing the usefulness of the Heartfelt1 device in patients suffering from heart failure, who have peripheral oedema. The device is non-contact and does not requires patient compliance to work.
- Conditions
- Heart Failure, Diastolic, Edema Brain, Decompensated Heartfailure
- Trial name
- NCT02993601
- Testing
- Heartfelt-1, Weighing scales, Medical grading of oedema
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Heartfelt Technologies
Heart Failure
V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure
The purpose of the trial is to evaluate the safety, usability and performance of the V-LAP™ System in adult subjects with New York Heart Association (NYHA) Class III Heart Failure.
- Trial name
- VECTOR-HF (NCT03775161)
- Testing
- V-LAP™ System
- Where
- 2 sites in Germany, Italy
- Volunteers
- 45 people
- Sponsor
- Vectorious Medical Technologies Ltd.
Heart Failure, Heart Failure, Diastolic
RESPONDER-HF Trial
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
- Trial name
- NCT05425459
- Testing
- Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 750 people
- Sponsor
- Corvia Medical
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systolic, Heart Failure, Diastolic
Physiological Signals, Activity and Posture for Surface Mounted Insertable Cardiac Monitor in Heart Failure Study
To characterize the physiological signals collected from a Wearable Cardiac Monitor (WCM) prototype device in subjects with heart failure and preserved ejection fraction (HFpEF) and compare against signals from subjects with…
- Trial name
- HAPI-HF (NCT04112576)
- Testing
- Wearable cardiac monitor
- Where
- 3 sites in United States, Singapore and 1 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Heart Failure
Avicena LVDP Validation Study
The purpose of the study is to determine the relationship between non-invasive measurement of left ventricular diastolic pressure (LVDP) using the Vivio System, compared with invasively measured LVDP via direct measurement during…
- Trial name
- NCT05633004
- Testing
- Vivio
- Where
- United States
- Volunteers
- 406 people
- Sponsor
- Ventric Health, LLC
Heart Failure
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.
- Trial name
- NCT00775840
- Testing
- Candesartan
- Where
- 37 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Takeda
Heart Failure
Indicor Validation
The study is designed to repeat an initial training set study conducted at Johns Hopkins Medical Center, comparing a new investigational device, Indicor, a non-invasive tool for estimating left ventricular end diastolic pressure…
- Trial name
- NCT03430102
- Testing
- Indicor
- Where
- 4 sites in United States
- Volunteers
- 289 people
- Sponsor
- Vixiar Medical, Inc.
Heart Failure
Correlation of Non-invasive Assessment, Using C.A 2.0 Device, Versus Invasive Assessment of LVEDP
The purpose of the study is to determine the accuracy of non-invasive assessment of LVEDP using the investigational device C.A 2.0.
- Trial name
- NCT02099448
- Where
- Israel
- Volunteers
- 41 people
- Sponsor
- CorAlert Ltd.
Heart Failure
Correlating Noninvasive Cardiovascular Measures to Left Ventricular End Diastolic Pressure in Heart Failure
HF001 is a prospective observational study utilizing non-invasive medical devices that may be able to discriminate changes in heart failure while acutely decompensated patients undergo routine interventional therapies in a…
- Trial name
- NCT02406820
- Testing
- Non-invasive hemodynamic monitoring (CVInsight™ [CVI])
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Intelomed, Inc.